A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, Trisomy 12 and 13q Deletion
Test Code13573
CPT Codes
88271 (x2), 88275
Includes
If results are not possible from the submitted specimen, the test order will be cancelled and replaced by non-orderable test Cytogenetics Communication.
Preferred Specimen
5 mL whole blood or 3 mL bone marrow collected in a sodium heparin (green-top) tube
Minimum Volume
3 mL whole blood • 1 mL bone marrow
Other Acceptable Specimens
Whole blood or bone marrow collected in: Sodium heparin (royal blue-top) tube, sodium heparin lead-free (tan-top) tube, or EDTA (lavender-top) tube
Instructions
Clinical history and reason for referral are required with test order. Prior therapy and bone marrow transplant history should be provided with test order.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Preferred
Refrigerated: Acceptable
Frozen: Unacceptable
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Refrigerated: Acceptable
Frozen: Unacceptable
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 5 days
Clinical Significance
The most common prognostically established cytogenetic abnormalities in CLL/SLL are 13q14 deletion, +12, TP53 (17p) deletion and ATM (11q) deletion. Although all these aberrations can be detected using the CLL/SLL FISH panel, trisomy 12 and 13q deletion status can be ordered separately, 13q deletion is associated with a favorable prognosis in CLL/SLL and it is also seen in other lymphoproliferative disorders. Trisomy 12 is strongly associated with CLL/SLL and less frequently with other lymphoproliferative disorders. In CLL/SLL patients, trisomy 12 is often characterized by a lymphocytic proliferation of cells with atypical immunophenotype and lymphocyte morphology and an intermediate prognosis.